HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $15
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $12 to $15.
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $12 to $15.